181 related articles for article (PubMed ID: 26251030)
1. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.
Jang S; Yu XM; Odorico S; Clark M; Jaskula-Sztul R; Schienebeck CM; Kupcho KR; Harrison AD; Winston-McPherson GN; Tang W; Chen H
Cancer Gene Ther; 2015 Aug; 22(8):410-6. PubMed ID: 26251030
[TBL] [Abstract][Full Text] [Related]
2. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
[TBL] [Abstract][Full Text] [Related]
3. Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer.
Patel PN; Yu XM; Jaskula-Sztul R; Chen H
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S497-504. PubMed ID: 24419754
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Zhang L; Boufraqech M; Lake R; Kebebew E
Oncotarget; 2016 Mar; 7(13):16517-28. PubMed ID: 26934320
[TBL] [Abstract][Full Text] [Related]
6. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
7. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells.
Greenberg VL; Williams JM; Cogswell JP; Mendenhall M; Zimmer SG
Thyroid; 2001 Apr; 11(4):315-25. PubMed ID: 11349829
[TBL] [Abstract][Full Text] [Related]
9. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
11. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.
Yu XM; Jaskula-Sztul R; Ahmed K; Harrison AD; Kunnimalaiyaan M; Chen H
Mol Cancer Ther; 2013 Jul; 12(7):1276-87. PubMed ID: 23594881
[TBL] [Abstract][Full Text] [Related]
13. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
14. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
15. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM
Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
17. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
Marlow LA; Bok I; Smallridge RC; Copland JA
Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
19. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
20. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
